S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Muñoz, 1997, Epidemiology of gastric cancer and perspectives for prevension, Salud Publica Mex, 39, 318, 10.1590/S0036-36341997000400010 Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalance across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world, J Clin Oncol, 24, 2137, 10.1200/JCO.2005.05.2308 Inoue, 2005, Epidemiology of gastric cancer in Japan, Postgrad Med J, 81, 419, 10.1136/pgmj.2004.029330 Murad, 1993, Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer, Cancer, 72, 37, 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P Glimelius, 1994, Initial or delayed chemotherapy with best supportive care in advanced gastric cancer, Ann Oncol, 5, 189, 10.1093/oxfordjournals.annonc.a058778 Pyrhönen, 1995, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer, Br J Cancer, 71, 587, 10.1038/bjc.1995.114 Macdonald, 1980, 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer, Ann Intern Med, 93, 533, 10.7326/0003-4819-93-4-533 Vanhoefer, 2000, J Clin Oncol, 18, 2648, 10.1200/JCO.2000.18.14.2648 Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130 Preusser, 1989, Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer, J Clin Oncol, 7, 1310, 10.1200/JCO.1989.7.9.1310 Wilke, 1990, High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer—a phase II study in elderly patients or patients with cardiac risk, Invest New Drugs, 8, 65, 10.1007/BF00216926 Findlay, 1994, A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF), Ann Oncol, 5, 609, 10.1093/oxfordjournals.annonc.a058932 Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429 Kang, 2006, Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results, Proc Am Soc Clin Oncol, LBA4018, 10.1200/jco.2006.24.18_suppl.lba4018 Cunningham, 2008, Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149 Shirasaka, 1996, Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators, Anticancer Drugs, 7, 548, 10.1097/00001813-199607000-00010 Sugimachi, 1999, An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers, Oncology, 57, 202, 10.1159/000012032 Sakata, 1998, Late phase II study of novel oral fluoropyrimidine aniticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients, Eur J Cancer, 34, 1715, 10.1016/S0959-8049(98)00211-1 Koizumi, 2000, Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer, Oncology, 58, 191, 10.1159/000012099 Koizumi, 2003, Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer, Br J Cancer, 89, 2207, 10.1038/sj.bjc.6601413 1998, Japanese classification of gastric carcinoma, 2nd English edn, Gastric Cancer, 1, 10, 10.1007/PL00011681 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Boku, 2007, Randomized phase III study of 5–fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG9912), Proc Am Soc Clin Oncol, LBA4513, 10.1200/jco.2007.25.18_suppl.lba4513 Ajani, 2005, Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma, J Clin Oncol, 23, 6957, 10.1200/JCO.2005.01.917 Shimada, 1996, Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations, Xenobiotica, 26, 395, 10.3109/00498259609046718 Ajani, 2006, MultiCentre phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma, J Clin Oncol, 24, 663, 10.1200/JCO.2005.04.2994 Sakuramoto, 2007, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, N Engl J Med, 357, 1810, 10.1056/NEJMoa072252 Nagashima, 2005, Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer, Gastric Cancer, 8, 6, 10.1007/s10120-004-0306-3 Ilson, 2007, Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?, J Clin Oncol, 25, 3188, 10.1200/JCO.2006.10.2210